Clinical Trials

Inclusion Criteria:

- Patients with localized leiomyosarcoma (LMS) of extremity, body wall or
retroperitoneum.

- Grade 2 or 3, or high-grade LMS.

- Tumor size >5 cm in greatest dimension.

- Primary tumor amenable to complete resection.

- There is no age requirement.

- Participant agrees to receive neoadjuvant doxorubicin and ifosfamide combination
chemotherapy.

- If pre-operative radiation is administered, it must be administered after
chemotherapy. Post-operative radiation may be administered.

- Archival tumor tissue (either frozen sample, tissue block containing tumor, or minimum
of 4 unstained slides and 1 H&E stained slide) from diagnostic or pre-treatment biopsy
available for study research.

Exclusion Criteria:

• Any exception to Inclusion Criteria.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/5/23. Questions regarding updates should be directed to the study team contact.